🇫🇷 IPN.PA — Ipsen S.A.

Salud Mantener
← Volver

Precio actual

155,80 EUR

Máx. histórico

172,90

182 días

Caída desde máximo

-9,89%

Rango 52 semanas

115,60 – 174,00

Variación hoy

+1,70%

Cierre anterior

153,20

Rango de hoy

153,30 – 155,90

Volumen hoy

107.342

Peor caída histórica

-75,62%

30/08/2018 → 18/03/2020

Recuperado en 2157 días

Volatilidad anualizada ⓘ

30,51%

Información
Nombre completo
Ipsen S.A.
Divisa
EUR
Mercado
Paris
Sector
Salud
Industria
Drug Manufacturers - Specialty & Generic
Empleados
5.535
PER ⓘ
25,21 (puede no estar actualizado)
Dividend yield
1,04% (puede no estar actualizado)
Precio objetivo analistas
161,92 EUR (puede no estar actualizado)
Primera cotización
07/12/2005
Precio actualizado
hace 20 horas
Sobre la empresa

Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience in North America, Europe, and internationally. It engages in the development of Somatuline for neuroendocrine tumors and acromegaly indications; and Dysport for motor muscular disorders and medical aesthetics indications; and Decapeptyl for advanced metastatic prostate cancer, uterine fibroids, central precocious puberty, endometriosis, female infertility, and early-stage breast cancer in combination with hormone therapy. The company also develops Cabometyx for renal cell carcinoma, second line hepatocellular carcinoma, differentiated thyroid cancer, and neuroendocrine tumors; Onivyde for second-line metastatic pancreatic cancer; and Bylvay for the treatment of progressive familial intrahepatic cholestasis and cholestatic pruritus in patients with both PFIC and Alagille syndrome. In addition, it is involved in the development of Iqirvo for the second line treatment for primary biliary cholangitis; Sohonos for the treatment to reduce new, abnormal bone formation in soft and connective tissues, in people living with ultra-rare bone disease, and fibrodysplasia ossificans progressiva; and IPN60340 in Phase I/II clinical trial for first line acute myeloid leukemia indications. Further, the company develops Tazverik + rituximab and lenalidomide in Phase III clinical trials for second line follicular lymphoma indications; Tovorafenib in Phase III clinical trials for first line pediatric low-grade gliomas indications; and IPN01194, IPN01195, IPN60300, and IPN01203 in Phase I for solid tumors indications; and IPN10200 in Phase II clinical trials for aesthetic and therapeutic indications. Ipsen S.A. was founded in 1929 and is headquartered in Paris, France.

Dividendos repartidos Total últimos 12 meses: 1,6000 EUR · Yield: 1,03%
Fecha de pago Importe por participación
03/06/2026 1,6000 EUR
04/06/2025 1,4000 EUR
30/05/2024 1,2000 EUR
02/06/2023 1,2000 EUR
31/05/2022 1,2000 EUR
31/05/2021 1,0000 EUR
03/06/2020 1,0000 EUR
31/05/2019 1,0000 EUR
04/06/2018 1,0000 EUR
09/06/2017 0,8500 EUR
02/06/2016 0,8500 EUR
29/05/2015 0,8500 EUR
09/06/2014 0,8000 EUR
05/06/2013 0,8000 EUR
06/06/2012 0,8000 EUR
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
21/01/2020 81,55 82,15 80,45 82,05 +0,49% 2,08% 84.270
20/01/2020 82,25 82,40 80,80 81,65 -0,85% 1,95% 71.951
17/01/2020 81,60 82,75 80,95 82,35 +1,10% 2,21% 158.256
16/01/2020 80,45 81,80 80,10 81,45 +0,37% 2,11% 193.779
15/01/2020 76,45 81,15 76,15 81,15 +6,50% 6,54% 259.613
14/01/2020 77,55 77,55 75,35 76,20 -1,68% 2,84% 192.139
13/01/2020 77,50 78,30 77,05 77,50 -0,13% 1,61% 118.076
10/01/2020 78,85 79,50 77,40 77,60 -1,27% 2,66% 145.779
09/01/2020 81,50 82,65 78,40 78,60 -4,50% 5,21% 220.444
08/01/2020 83,05 83,25 81,30 82,30 -1,08% 2,35% 122.075
07/01/2020 78,70 83,35 78,70 83,20 +5,79% 5,91% 265.597
06/01/2020 78,45 78,90 76,65 78,65 -0,94% 2,87% 170.706
03/01/2020 79,35 79,70 78,25 79,40 +0,06% 1,83% 87.150
02/01/2020 79,05 80,55 79,05 79,35 +0,44% 1,90% 112.148
31/12/2019 79,15 79,50 78,50 79,00 -0,63% 1,26% 45.585
30/12/2019 78,90 80,75 78,50 79,50 +0,57% 2,85% 153.866
27/12/2019 79,00 80,15 78,85 79,05 +0,06% 1,65% 62.316
25/12/2019 79,00 79,00 79,00 79,00 +0,00% 0,00% 0
24/12/2019 79,20 80,20 78,30 79,00 -0,44% 2,40% 45.570
23/12/2019 80,45 81,00 79,35 79,35 -1,86% 2,05% 82.303
20/12/2019 80,10 80,85 79,30 80,85 +0,94% 1,94% 205.865
19/12/2019 76,50 80,10 76,50 80,10 +4,50% 4,71% 257.100
18/12/2019 78,80 79,55 74,20 76,65 -4,07% 6,79% 374.019
17/12/2019 80,45 81,20 79,25 79,90 -0,68% 2,42% 112.958
16/12/2019 78,50 80,45 78,15 80,45 +2,61% 2,93% 166.913
13/12/2019 80,25 80,40 78,40 78,40 -1,63% 2,49% 143.723
12/12/2019 79,00 79,70 77,45 79,70 +1,14% 2,85% 238.491
11/12/2019 79,10 79,20 76,75 78,80 -0,38% 3,10% 209.264
10/12/2019 79,75 80,35 77,30 79,10 -0,82% 3,82% 188.251
09/12/2019 82,95 83,10 79,65 79,75 -5,12% 4,16% 371.871